Pacific Biosciences of California (Pacific Biosciences of California) Change In Working Capital

: $-59.0 Mil (TTM As of Dec. 2023)

View and export this data going back to 2010. Start your Free Trial

Pacific Biosciences of California's change in working capital for the quarter that ended in Dec. 2023 was $-7.7 Mil.

Pacific Biosciences of California's change in working capital for the fiscal year that ended in Dec. 2023 was $-59.0 Mil.

It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement. Not by calculating the number changes in each periods' working capital (Total Current Assets minus Total Current Liabilities).

Pacific Biosciences of California Change In Working Capital Historical Data

The historical data trend for Pacific Biosciences of California's Change In Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacific Biosciences of California Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Working Capital

Get a 7-Day Free Trial

-3.00

-3.29

20.33

-53.97

-58.96

Pacific Biosciences of California Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Change In Working Capital	Get a 7-Day Free Trial															-5.68	-43.13	4.51	-12.60	-7.74

Pacific Biosciences of California Change In Working Capital Calculation

Change In Working Capital for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-59.0 Mil.

Working Capital is a measure of a company's short term liquidity or its ability to cover short term liabilities. It is defined as the difference between a company's current assets and current liabilities.

Changes in Working Capital is reported in the cash flow statement since it is one of the major ways in which net income can differ from operating cash flow. It is calculated by adding the items under "Change in operating assets and liabilities" (may refer to a different name for different company) section in Cash Flow Statement.

Use Wal-Mart Stores Inc (Jan 2014, Annual Data) as an example: Source: Wal-Mart Stores Inc 2014-01-31 10-K from SEC

Consolidated Statements of Cash Flows	Fiscal Years Ended	January 31,	(Amounts in millions)
Cash flows from operating activities:	2014	2013	2012
Changes in certain assets and liabilities, net of effects of acquisitions:
Receivables, net	(566)	(614)	(796)
Inventories	(1,667)	(2,759)	(3,727)
Accounts payable	531	1,061	2,687
Accrued liabilities	103	271	(935)
Accrued income taxes	(1,224)	981	994

For 2014-01-31, add all the items under 2014 collum together, Change in Working Capital was (566) + (1,667) + 531 + 103 + (1,224) = $ (2,823) Mil.

Pacific Biosciences of California Change In Working Capital Related Terms

Thank you for viewing the detailed overview of Pacific Biosciences of California's Change In Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Pacific Biosciences of California (Pacific Biosciences of California) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pacific Biosciences of California Inc (NAS:PACB) » Definitions » Change In Working Capital

Comparable Companies

Traded in Other Exchanges

P09:Germany P09:Germany

Address

1305 O’Brien Drive, Menlo Park, CA, USA, 94025

Website

https://www.pacb.com

Pacific Biosciences of California Inc is a biotechnology company focused on the design, development, and commercialization of tools for biological research. The company develops sequencing systems to assist in resolving genetically complex problems. Its sequencing systems provide access to a wide range of applications and are designed for expandable improvements to performance capability. The majority of the company's revenue is derived from North America, followed by Asia and Europe.

Executives

Oene Mark Van	officer: Chief Operating Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Christian O Henry	director	9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
David W Meline	director	3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000
Susan G. Kim	officer: Chief Financial Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Jeff Eidel	officer: See Remarks	1305 O'BRIEN DR., MENLO PARK CA 94025
Michele Farmer	officer: Chief Accounting Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
William W. Ericson	director	777 MARINERS ISLAND BOULEVARD, SUITE 550, SAN MATEO CA 94404
Peter Fromen	officer: Chief Commercial Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Hannah Valantine	director	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Michael Hunkapiller	director	400 HAMILTON AVENUE, 4TH FLOOR, PALO ALTO CA 94301
Eric Schaefer	officer: VP Chief Accounting Officer	1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Kathy Ordonez	director	3 GIRALDA FARMS, C/O QUEST DIAGNOSTICS, MADISON NJ 07940
Randall S Livingston	director
Lucy Shapiro	director	10210 GENETIC CENTER COURT, SAN DIEGO CA 92121
David Botstein	director	1380 WILLOW ROAD, PACIFIC BIOSCIENCES OF CALIFORNIA INC, MENLO PARK CA 94025